Leflunomide ratiopharm: Uses, Dosage & Side Effects
A generic disease-modifying antirheumatic drug (DMARD) containing leflunomide, used for the treatment of active rheumatoid arthritis and psoriatic arthritis in adults
Leflunomide ratiopharm is a generic disease-modifying antirheumatic drug (DMARD) containing the active substance leflunomide. It is used to treat active rheumatoid arthritis and active psoriatic arthritis in adults. Unlike simple painkillers that only mask symptoms, leflunomide works by modulating the overactive immune system to reduce joint inflammation, slow disease progression, and prevent permanent joint damage. Leflunomide ratiopharm is bioequivalent to the originator brand Arava and is recommended in international guidelines from the American College of Rheumatology (ACR) and the European Alliance of Associations for Rheumatology (EULAR) as an alternative first-line conventional synthetic DMARD.
Quick Facts: Leflunomide ratiopharm
Key Takeaways
- Leflunomide ratiopharm is a generic DMARD bioequivalent to Arava, used to treat active rheumatoid arthritis and psoriatic arthritis by modulating the immune system to reduce inflammation and slow joint destruction, as recommended by ACR and EULAR guidelines.
- Treatment typically begins with a 100 mg loading dose for 3 days (using a different leflunomide product for loading), followed by a maintenance dose of 10–20 mg once daily; clinical improvement may take approximately 4 weeks, with further improvement over 4–6 months.
- Leflunomide is strictly contraindicated in pregnancy and breastfeeding due to the risk of serious birth defects; women of childbearing potential must use reliable contraception during treatment and for up to 2 years after stopping, unless an accelerated washout procedure is performed.
- Regular monitoring of liver function tests, complete blood counts, and blood pressure is mandatory before and during treatment to detect potentially serious hepatotoxicity, bone marrow suppression, or hypertension.
- Common side effects include diarrhea, nausea, hair loss, elevated liver enzymes, and mild blood pressure increase; seek immediate medical attention for signs of severe liver problems, serious infections, or severe skin reactions.
What Is Leflunomide ratiopharm and What Is It Used For?
Leflunomide ratiopharm contains the active substance leflunomide, an isoxazole immunomodulatory agent that belongs to the group of disease-modifying antirheumatic drugs (DMARDs). It is a generic formulation manufactured by ratiopharm (a Teva Pharmaceutical Industries company) and is bioequivalent to the originator brand Arava, meaning it contains the same active substance in the same amount and achieves the same blood levels and therapeutic effects. Unlike nonsteroidal anti-inflammatory drugs (NSAIDs) or corticosteroids that primarily provide symptomatic relief, DMARDs such as leflunomide target the underlying disease process to slow or halt the progression of joint damage.
Leflunomide was first approved by the U.S. Food and Drug Administration (FDA) in 1998 and subsequently by the European Medicines Agency (EMA) for the treatment of rheumatoid arthritis and psoriatic arthritis in adults. Generic versions, including Leflunomide ratiopharm, have been available since the patent expiry of the originator product, providing more affordable access to this important medication. Generic leflunomide products must meet the same rigorous quality, safety, and efficacy standards as the originator brand, as required by regulatory authorities worldwide.
Leflunomide is a prodrug that is rapidly and almost completely converted in the gastrointestinal tract and liver into its active metabolite, teriflunomide (also known as A77 1726). Teriflunomide exerts its therapeutic effect primarily by inhibiting the mitochondrial enzyme dihydroorotate dehydrogenase (DHODH), which is a key enzyme in the de novo biosynthesis of pyrimidines. Activated lymphocytes, the immune cells responsible for the inflammatory cascade in autoimmune arthritis, rely heavily on de novo pyrimidine synthesis for their rapid proliferation. By blocking this pathway, leflunomide selectively reduces the proliferation of these activated lymphocytes without significantly affecting cells that can obtain pyrimidines through the salvage pathway.
Rheumatoid arthritis is a chronic autoimmune disease that primarily affects the joints, causing inflammation, swelling, pain, stiffness, and progressive joint destruction if left untreated. Beyond the joints, rheumatoid arthritis can cause systemic symptoms including fatigue, loss of appetite, fever, and anemia. The disease affects approximately 0.5–1% of the global adult population, with women being affected two to three times more frequently than men. Early and effective treatment with DMARDs is essential to prevent irreversible joint damage and disability. Current international guidelines from the ACR (2021) and EULAR (2022) recommend initiating DMARD therapy as soon as the diagnosis of rheumatoid arthritis is confirmed.
Psoriatic arthritis is an inflammatory joint disease that occurs in association with psoriasis, a chronic skin condition characterized by red, scaly patches. Psoriatic arthritis affects approximately 30% of individuals with psoriasis and can cause significant joint pain, swelling, stiffness, and enthesitis (inflammation where tendons and ligaments attach to bone). Like rheumatoid arthritis, untreated psoriatic arthritis can lead to permanent joint damage and functional disability. Leflunomide has been shown in clinical trials to improve both the joint symptoms and the skin manifestations of psoriatic arthritis.
The efficacy of leflunomide in rheumatoid arthritis has been established in several large, randomized controlled trials, including the pivotal MN301, MN302, and MN303 studies. These landmark trials demonstrated that leflunomide significantly reduces disease activity, improves physical function, and slows radiographic joint damage compared to placebo, with efficacy comparable to methotrexate and sulfasalazine. International guidelines from the ACR (2021) and EULAR (2022) recommend leflunomide as an alternative first-line conventional synthetic DMARD, particularly for patients who cannot tolerate methotrexate or for whom methotrexate is contraindicated.
What Should You Know Before Taking Leflunomide ratiopharm?
Contraindications
There are several important situations where Leflunomide ratiopharm must not be used. Understanding these contraindications is essential for safe treatment and the prevention of serious, potentially life-threatening adverse events. You should not take Leflunomide ratiopharm if any of the following apply:
- Allergy to leflunomide: Known hypersensitivity to leflunomide or any of the excipients. This includes any previous severe skin reaction (such as Stevens-Johnson syndrome, toxic epidermal necrolysis, or erythema multiforme) associated with leflunomide use, as well as allergy to teriflunomide (used to treat multiple sclerosis).
- Liver disease: Any significant hepatic impairment or active liver disease, as leflunomide is hepatotoxic and metabolized in the liver.
- Moderate to severe kidney impairment: Significantly reduced kidney function, as there is insufficient clinical experience in this population and the risk of adverse effects is increased.
- Severe hypoproteinemia: Markedly low blood protein (albumin) levels, such as in nephrotic syndrome, which can increase the free (unbound) drug concentration and enhance toxicity.
- Immunodeficiency: Severe immunodeficiency states (including AIDS), as further immunosuppression with leflunomide could lead to overwhelming infections.
- Bone marrow dysfunction: Significantly impaired bone marrow function or low baseline counts of red blood cells, white blood cells, or platelets, as leflunomide can cause further myelosuppression.
- Serious active infections: Any uncontrolled serious infection, as leflunomide suppresses immune function and could worsen the infection.
- Pregnancy and breastfeeding: Leflunomide is strictly contraindicated in pregnancy (or suspected pregnancy) and during breastfeeding due to the risk of serious birth defects and potential harm to the nursing infant.
Warnings and Precautions
Leflunomide can cause serious liver damage, including rare cases of fatal liver failure. Your doctor must check your liver function tests (ALT/SGPT) before starting treatment and at regular intervals during therapy, at least monthly for the first 6 months and every 6–8 weeks thereafter. If ALT rises to more than 2 times the upper limit of normal, dose reduction or discontinuation may be required. Stop taking Leflunomide ratiopharm and seek medical attention immediately if you develop symptoms of liver problems: unexplained fatigue, abdominal pain, dark urine, or yellowing of the skin or eyes (jaundice).
Leflunomide can affect your blood, liver, lungs, and peripheral nerves. It can also cause serious allergic reactions, including Drug Reaction with Eosinophilia and Systemic Symptoms (DRESS), or increase the risk of serious infections. Your doctor will order regular blood tests before and throughout your treatment to monitor your complete blood count (including white blood cells, red blood cells, and platelets) and liver enzymes.
Drug Reaction with Eosinophilia and Systemic Symptoms (DRESS) is a rare but potentially life-threatening allergic reaction. It typically begins with flu-like symptoms and a facial rash, followed by widespread rash, high fever, elevated liver enzymes, and an increase in a type of white blood cells called eosinophils, along with enlarged lymph nodes. Seek immediate medical attention if these symptoms develop.
Tell your doctor before starting treatment if you have ever had interstitial lung disease (inflammation of the lungs), if you have ever had tuberculosis or been in close contact with someone who has or has had tuberculosis, or if you are a man wishing to father a child. Although data are limited, it cannot be excluded that leflunomide passes into seminal fluid; men should use reliable contraception during treatment. Men wishing to conceive should consult their doctor, who may recommend discontinuing the medication and performing an accelerated drug elimination procedure. A blood test should confirm adequate washout, and you should then wait at least an additional 3 months before attempting conception.
Your doctor should also regularly monitor your blood pressure during treatment, as leflunomide can cause elevated blood pressure. Tell your doctor if you develop unexplained persistent diarrhea, as additional investigations may be needed. If you are planning or have recently undergone major surgery, or if you have an unhealed surgical wound, inform your doctor, as leflunomide may impair wound healing.
Children and Adolescents
Leflunomide ratiopharm is not recommended for use in children and adolescents under 18 years of age. The safety and efficacy of leflunomide have not been adequately established in the pediatric population. Juvenile idiopathic arthritis (JIA) in children is managed with other approved DMARDs such as methotrexate, and biologic therapies where appropriate.
Pregnancy and Breastfeeding
Leflunomide ratiopharm is strictly contraindicated during pregnancy. Leflunomide has demonstrated teratogenic effects in animal studies and poses a serious risk of birth defects in humans. Women of childbearing potential must use reliable contraception throughout the entire course of treatment and for a period after stopping the drug. The active metabolite teriflunomide has a very long elimination half-life (approximately 1–4 weeks), meaning it can remain in the body for up to 2 years after the last dose without an accelerated elimination procedure.
If you are planning to become pregnant after completing treatment, you must ensure that the drug has been sufficiently eliminated from your body. Without intervention, this can take up to 2 years. However, this period can be shortened to a few weeks by taking specific medications (cholestyramine 8 g three times daily for 11 days, or activated charcoal 50 g four times daily for 11 days) that accelerate the elimination of leflunomide from the body. In both cases, a blood test must confirm that the plasma concentration of the active metabolite teriflunomide is below 0.02 mg/L on two separate occasions at least 14 days apart. You should then wait at least one additional month before attempting to conceive.
If you suspect you are pregnant during treatment or within 2 years of stopping Leflunomide ratiopharm, contact your doctor immediately for a pregnancy test. If the test confirms pregnancy, your doctor may recommend the accelerated elimination procedure to reduce the risk to your unborn child as quickly as possible.
Leflunomide ratiopharm must not be used during breastfeeding, as the active metabolite teriflunomide may be excreted into breast milk and could cause harm to the nursing infant.
Driving and Operating Machinery
Leflunomide may cause dizziness, which can impair your ability to concentrate and react. If you feel affected, do not drive a vehicle or operate machinery until the symptoms resolve. This is particularly important during the initial weeks of treatment or when the dose is adjusted.
How Does Leflunomide ratiopharm Interact with Other Drugs?
Drug interactions with leflunomide can occur through several mechanisms. The active metabolite teriflunomide inhibits several cytochrome P450 enzymes (particularly CYP2C8) and drug transporters (including BCRP and OAT3), which can increase the blood levels and effects of certain co-administered medications. Additionally, some combinations increase the risk of hepatotoxicity or myelosuppression. It is essential to inform your healthcare provider about all medications you are taking, including prescription drugs, over-the-counter medicines, and herbal supplements.
Major Interactions
| Interacting Drug | Effect | Action Required |
|---|---|---|
| Methotrexate and other immunosuppressants | Increased risk of hepatotoxicity and myelosuppression; combination not generally recommended | Combination should be avoided or used only under close specialist supervision with frequent monitoring |
| Warfarin and other oral anticoagulants | Increased INR and bleeding risk due to CYP2C9 inhibition by teriflunomide | Close INR monitoring required; dose adjustment of anticoagulant may be needed |
| Teriflunomide (for multiple sclerosis) | Both drugs share the same active metabolite; concurrent use leads to excessive immunosuppression | Do not use simultaneously |
| Repaglinide, pioglitazone, rosiglitazone | Teriflunomide inhibits CYP2C8, potentially increasing blood levels of these diabetes medications | Monitor blood glucose closely; dose adjustment may be needed |
| Cholestyramine or activated charcoal | Rapidly reduces plasma levels of the active metabolite teriflunomide by interrupting enterohepatic recirculation | Used therapeutically for drug elimination; avoid during active treatment unless washout is intended |
Other Notable Interactions
| Interacting Drug | Effect | Action Required |
|---|---|---|
| Rosuvastatin, simvastatin, atorvastatin, pravastatin | Teriflunomide inhibits BCRP and OATP1B1 transporters, increasing statin blood levels and risk of muscle toxicity | Monitor for signs of myopathy; consider statin dose reduction |
| Duloxetine | Teriflunomide may increase duloxetine levels via CYP1A2 inhibition | Monitor for adverse effects; dose adjustment may be needed |
| Theophylline | Teriflunomide inhibits CYP1A2, potentially increasing theophylline levels | Monitor theophylline levels closely |
| Oral contraceptives (ethinylestradiol, levonorgestrel) | Teriflunomide may alter hormone levels, though contraceptive efficacy is generally maintained | Consider using an additional barrier method; discuss with your doctor |
| Ciprofloxacin, cefaclor, penicillin G | Teriflunomide inhibits OAT3 transporter, potentially increasing antibiotic levels | Monitor for adverse effects of the antibiotic |
If you need to be vaccinated, consult your doctor first. Live vaccines must not be given during treatment with Leflunomide ratiopharm or for a period after treatment is stopped, as the immunosuppressive effect of the drug can lead to an inadequate immune response or even infection from the live vaccine strain. Inactivated vaccines may be given, but their effectiveness may be reduced. Your doctor will advise on the appropriate waiting period.
Food, Drink, and Alcohol
Leflunomide ratiopharm can be taken with or without food. However, alcohol consumption should be avoided during treatment, as both leflunomide and alcohol are metabolized in the liver, and concurrent use significantly increases the risk of liver damage. Even moderate alcohol intake can compound the hepatotoxic potential of leflunomide. If you continue to use NSAIDs (such as ibuprofen or naproxen) or corticosteroids (such as prednisolone), you may continue taking these after starting leflunomide, but inform your doctor so that appropriate monitoring can be arranged.
This list of interactions is not exhaustive. Always tell your doctor or pharmacist about all medicines you are taking, have recently taken, or might take, including herbal supplements and over-the-counter products.
What Is the Correct Dosage of Leflunomide ratiopharm?
Always take Leflunomide ratiopharm exactly as your doctor has prescribed. The dose is individualized based on your diagnosis, disease severity, and tolerance. Do not change your dose without consulting your doctor. Leflunomide tablets should be swallowed whole with an adequate amount of water and can be taken with or without food.
Adults — Rheumatoid Arthritis
Rheumatoid Arthritis Dosage
- Loading dose: 100 mg once daily for 3 days (using a 100 mg leflunomide product)
- Maintenance dose: 10 mg or 20 mg once daily, depending on disease severity
- Onset of action: Approximately 4 weeks; further improvement may continue over 4–6 months
- Duration: Long-term treatment; do not stop without medical advice
The loading dose of 100 mg for the first 3 days is designed to achieve therapeutic plasma concentrations of the active metabolite teriflunomide more rapidly, given its long elimination half-life of approximately 1–4 weeks. Since Leflunomide ratiopharm is available as 10 mg tablets, a separate 100 mg leflunomide product may be used for the loading dose. Some clinicians may choose to omit the loading dose to improve gastrointestinal tolerability, starting directly at the maintenance dose, although this approach means that steady-state concentrations will take longer to achieve (approximately 2 months). Your rheumatologist will determine the most appropriate approach for your individual situation.
Adults — Psoriatic Arthritis
Psoriatic Arthritis Dosage
- Loading dose: 100 mg once daily for 3 days
- Maintenance dose: 20 mg once daily
- Duration: Long-term treatment as directed by your doctor
Clinical trials in psoriatic arthritis have demonstrated that leflunomide at a dose of 20 mg daily significantly improves both joint symptoms (swelling, tenderness, pain) and skin manifestations (psoriatic skin lesions) compared to placebo. The treatment is intended for long-term use to maintain disease control and prevent disease flares. For the 20 mg maintenance dose, two Leflunomide ratiopharm 10 mg tablets may be taken together, or your doctor may prescribe a 20 mg leflunomide product.
Elderly Patients
No dose adjustment is necessary for elderly patients based on age alone. However, elderly patients may have reduced hepatic or renal function, which should be assessed before starting treatment. More frequent monitoring of liver function and blood counts may be warranted in older patients. The risk of adverse effects, particularly hepatotoxicity and myelosuppression, may be increased in the elderly, and careful clinical supervision is recommended.
Missed Dose
If you forget to take a dose, take it as soon as you remember, unless it is nearly time for your next scheduled dose. In that case, skip the missed dose and take the next dose at the usual time. Do not take a double dose to compensate for a forgotten dose. Maintaining a consistent daily dosing schedule helps ensure stable drug levels and optimal disease control.
Overdose
If you take more Leflunomide ratiopharm than prescribed, or if an overdose is suspected, contact your doctor immediately or go to the nearest emergency department. There is no specific antidote for leflunomide overdose. The accelerated elimination procedure using cholestyramine or activated charcoal should be initiated promptly to reduce plasma levels of the active metabolite teriflunomide. Bring your tablets or the medication packaging with you if possible.
Overdose with leflunomide may result in exaggerated pharmacological effects, including severe immunosuppression, gastrointestinal toxicity, hepatotoxicity, and myelosuppression. Because of the long half-life of the active metabolite, symptoms may be prolonged. Cholestyramine or activated charcoal can significantly accelerate the elimination of teriflunomide and should be administered as soon as possible in an overdose situation. Hemodialysis is not effective for removing teriflunomide because it is highly protein-bound (over 99%).
What Are the Side Effects of Leflunomide ratiopharm?
Like all medicines, Leflunomide ratiopharm can cause side effects, although not everyone experiences them. Since it contains the same active substance as the originator brand Arava, the side effect profile is identical. Some side effects can be serious and require immediate medical attention. Your doctor will monitor you regularly with blood tests and clinical assessments to detect side effects early. If you experience any concerning symptoms, do not hesitate to contact your healthcare provider.
Stop taking Leflunomide ratiopharm and contact your doctor immediately if you experience: weakness, dizziness, or difficulty breathing (signs of severe allergic reaction); skin rash or sores in the mouth (possible Stevens-Johnson syndrome, toxic epidermal necrolysis, or DRESS); pallor, fatigue, or unusual bruising (signs of blood disorders); tiredness, abdominal pain, or jaundice (signs of liver problems); fever, sore throat, or persistent cough (signs of serious infection); or unusual tingling, weakness, or pain in your hands or feet (signs of peripheral neuropathy).
Common
May affect up to 1 in 10 people
- Mild decrease in white blood cell count (leukopenia)
- Mild allergic reactions
- Loss of appetite, weight loss
- Tiredness and weakness (asthenia)
- Headache, dizziness
- Abnormal skin sensations such as tingling (paresthesia)
- Mildly increased blood pressure
- Diarrhea, nausea, vomiting
- Mouth inflammation or oral mucosal changes
- Abdominal pain, colitis
- Elevated liver enzyme levels
- Hair loss (usually mild and reversible)
- Eczema, dry skin, rash, itching
- Tendinitis (tendon inflammation, typically in feet or hands)
- Increased creatine kinase levels
Uncommon
May affect up to 1 in 100 people
- Decreased red blood cells (anemia) and decreased platelets (thrombocytopenia)
- Decreased blood potassium levels
- Anxiety
- Taste changes
- Hives (urticaria)
- Tendon rupture
- Increased blood lipids (cholesterol and triglycerides)
- Decreased blood phosphate levels
Rare
May affect up to 1 in 1,000 people
- Increased eosinophils (eosinophilia); moderate decrease in all blood cell types (pancytopenia)
- Severely increased blood pressure
- Interstitial lung disease (inflammation in the lungs)
- Significantly elevated liver enzymes progressing to hepatitis or jaundice
- Severe infections (sepsis), which can be life-threatening
- Increased lactate dehydrogenase levels
Very Rare
May affect up to 1 in 10,000 people
- Severe reduction in certain white blood cells (agranulocytosis)
- Severe and potentially life-threatening allergic reactions (anaphylaxis)
- Vasculitis (inflammation of blood vessels, including cutaneous necrotizing vasculitis)
- Peripheral neuropathy (nerve damage in arms and legs)
- Pancreatitis (inflammation of the pancreas)
- Severe liver damage including liver failure or necrosis, which may be fatal
- Severe skin reactions: Stevens-Johnson syndrome, toxic epidermal necrolysis, erythema multiforme
Other Reported Effects
Additional adverse events reported with unknown frequency include: kidney failure, decreased uric acid levels, pulmonary hypertension, male infertility (which is reversible upon discontinuation), cutaneous lupus (rash and redness on sun-exposed skin areas), new onset or worsening of psoriasis, Drug Reaction with Eosinophilia and Systemic Symptoms (DRESS), and skin ulcers (round, open sores through which underlying tissue may be visible).
If you notice any side effects not listed here, or if any of the listed side effects become severe, contact your doctor, pharmacist, or nurse. You can also report suspected side effects to your national drug regulatory authority, such as the FDA MedWatch program in the United States, the Yellow Card Scheme (MHRA) in the United Kingdom, or the European Medicines Agency (EMA) pharmacovigilance system.
How Should You Store Leflunomide ratiopharm?
Keep this medicine out of the sight and reach of children at all times. Do not use Leflunomide ratiopharm after the expiry date stated on the carton and blister pack. The expiry date refers to the last day of the stated month. Store at room temperature, not exceeding 25°C. Protect from excessive moisture and heat.
Store the tablets in the original blister packaging to protect them from moisture and light. If the tablets come in a bottle container, ensure the bottle is kept tightly closed after each use. Do not transfer the tablets to other containers unless specifically designed for pharmaceutical storage.
Do not dispose of medications via wastewater or household waste. Return unused or expired medications to your pharmacist for safe disposal. These measures help protect the environment and prevent accidental exposure. Leflunomide is an immunosuppressive agent, and proper disposal is important to prevent inadvertent exposure to others, particularly pregnant women or women of childbearing potential.
What Does Leflunomide ratiopharm Contain?
Each Leflunomide ratiopharm film-coated tablet contains the active substance leflunomide 10 mg. The tablet is designed for oral administration and should be swallowed whole.
| Tablet Strength | Leflunomide Content | Appearance |
|---|---|---|
| 10 mg | 10 mg | White to off-white, round, film-coated tablet |
The inactive ingredients (excipients) in Leflunomide ratiopharm film-coated tablets typically include:
- Tablet core: Lactose monohydrate, maize starch, povidone (K25), crospovidone, colloidal anhydrous silica, and magnesium stearate.
- Film coating: Hypromellose (E464), titanium dioxide (E171), talc (E553b), and macrogol 8000.
Leflunomide ratiopharm tablets contain lactose monohydrate. If your doctor has told you that you have an intolerance to certain sugars, contact your doctor before taking this medicine. The amount of lactose per tablet is generally well below the threshold that causes symptoms in most lactose-intolerant individuals, but individual sensitivity varies.
The marketing authorization holder is ratiopharm GmbH (a Teva company). Leflunomide ratiopharm is one of several generic leflunomide products available on the market. While the active ingredient is identical across all leflunomide formulations, the excipients may vary slightly between manufacturers. If you are switching between different leflunomide brands, inform your doctor so they can monitor your response accordingly, although bioequivalence studies have confirmed comparable therapeutic performance.
Frequently Asked Questions About Leflunomide ratiopharm
Leflunomide ratiopharm is a disease-modifying antirheumatic drug (DMARD) used to treat active rheumatoid arthritis and active psoriatic arthritis in adults. It works by suppressing the overactive immune system that causes joint inflammation, swelling, pain, and progressive joint damage. Unlike painkillers that only provide symptomatic relief, leflunomide slows the progression of the disease and helps preserve joint function over the long term. It is a generic version of Arava and is recommended by ACR and EULAR guidelines as an alternative to methotrexate when methotrexate is not suitable.
Leflunomide ratiopharm contains the same active substance (leflunomide) as Arava and is bioequivalent, meaning it achieves the same blood levels and produces the same therapeutic effects. The main differences are in the manufacturer (ratiopharm/Teva vs. Sanofi-Aventis) and potentially minor differences in inactive ingredients (excipients). Generic medicines must meet the same rigorous quality, safety, and efficacy standards as the originator brand, as required by regulatory authorities such as the EMA and FDA. Generic leflunomide is typically available at a lower cost.
No. Leflunomide ratiopharm is strictly contraindicated in pregnancy because it can cause serious birth defects. Women of childbearing potential must use reliable contraception during treatment and for up to 2 years after stopping. However, this waiting period can be shortened to a few weeks by performing an accelerated drug elimination procedure using cholestyramine or activated charcoal, followed by blood tests to confirm that the active metabolite has been sufficiently cleared. Men wishing to father a child should also consult their doctor, as a washout procedure and a waiting period of at least 3 months may be recommended.
Regular blood tests are essential during treatment. Before starting, your doctor will check your complete blood count (white blood cells, red blood cells, platelets) and liver function tests (ALT/SGPT). During the first 6 months, liver enzymes should be monitored at least monthly. After 6 months, monitoring can be reduced to every 6–8 weeks. Your doctor will also regularly check your blood pressure, as leflunomide can cause hypertension. If liver enzymes become persistently elevated above 2 times the upper limit of normal, dose reduction or discontinuation may be required.
Alcohol consumption should be avoided during treatment with Leflunomide ratiopharm. Both leflunomide and alcohol are metabolized in the liver, and their combined use significantly increases the risk of liver damage (hepatotoxicity). Even moderate alcohol intake can compound the hepatotoxic potential of leflunomide. If you have concerns about alcohol use during treatment, discuss this openly with your doctor, who can provide personalized guidance based on your liver function and overall health status.
You may begin to notice improvement in your symptoms approximately 4 weeks after starting Leflunomide ratiopharm. Some patients experience continued improvement over 4 to 6 months of treatment. The initial loading dose (100 mg for 3 days) is designed to achieve therapeutic drug levels more rapidly. If your doctor omits the loading dose to improve tolerability, it may take somewhat longer to reach full efficacy. Leflunomide ratiopharm is intended for long-term use; do not stop the medication because you feel it is not working quickly enough without consulting your doctor.
References
This article is based on current international medical guidelines and peer-reviewed scientific literature. All medical claims are supported by evidence level 1A, the highest quality of evidence based on systematic reviews and randomized controlled trials.
- European Medicines Agency (EMA). Leflunomide — Summary of Product Characteristics. Updated 2025. Official European regulatory document for leflunomide-containing products.
- U.S. Food and Drug Administration (FDA). Arava (leflunomide) Prescribing Information. Sanofi-Aventis. Official U.S. prescribing information applicable to all leflunomide formulations.
- Fraenkel L, Bathon JM, England BR, et al. 2021 American College of Rheumatology Guideline for the Treatment of Rheumatoid Arthritis. Arthritis Care Res (Hoboken). 2021;73(7):924-939. doi:10.1002/acr.24596
- Smolen JS, Landewé RBM, Bergstra SA, et al. EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2022 update. Ann Rheum Dis. 2023;82(1):3-18. doi:10.1136/ard-2022-223356
- Strand V, Cohen S, Schiff M, et al. Treatment of active rheumatoid arthritis with leflunomide compared with placebo and methotrexate. Arch Intern Med. 1999;159(21):2542-2550. doi:10.1001/archinte.159.21.2542
- Emery P, Breedveld FC, Lemmel EM, et al. A comparison of the efficacy and safety of leflunomide and methotrexate for the treatment of rheumatoid arthritis. Rheumatology. 2000;39(6):655-665. doi:10.1093/rheumatology/39.6.655
- Kaltwasser JP, Nash P, Gladman D, et al. Efficacy and safety of leflunomide in the treatment of psoriatic arthritis and psoriasis: a multinational, double-blind, randomized, placebo-controlled clinical trial. Arthritis Rheum. 2004;50(6):1939-1950. doi:10.1002/art.20253
- World Health Organization (WHO). WHO Model List of Essential Medicines — 23rd List (2023). Geneva: WHO; 2023. Leflunomide is included as a disease-modifying agent in rheumatic disorders.
- Alcorn N, Saunders S, Madhok R. Benefit-risk assessment of leflunomide: an appraisal of leflunomide in rheumatoid arthritis 10 years after licensing. Drug Saf. 2009;32(12):1123-1134. doi:10.2165/11316650-000000000-00000
- Gossec L, Baraliakos X, Kerschbaumer A, et al. EULAR recommendations for the management of psoriatic arthritis with pharmacological therapies: 2019 update. Ann Rheum Dis. 2020;79(6):700-712. doi:10.1136/annrheumdis-2020-217159
Medical Editorial Team
This article has been written and reviewed by the iMedic Medical Editorial Team, consisting of licensed physicians with specialist qualifications in rheumatology, clinical pharmacology, and internal medicine. All content follows the GRADE evidence framework and adheres to international medical standards set by the WHO, EMA, FDA, ACR, and EULAR.
All articles undergo a rigorous multi-step review process: initial drafting by medical writers, clinical accuracy review by specialist physicians, evidence grading according to the GRADE framework, and final editorial quality assurance. Content is updated regularly to reflect new guidelines, research findings, and safety information.
iMedic follows Evidence Level 1A standards, drawing from systematic reviews, meta-analyses, and randomized controlled trials published in peer-reviewed journals. We reference established clinical guidelines from international medical organizations including the ACR, EULAR, WHO, EMA, and FDA.
For questions about our editorial process or to report inaccuracies, please visit our Editorial Standards page or contact our editorial team.